# Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

> **NCT04193059** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 1560 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04193059
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-20
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 1560 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193059, "Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04193059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*